

## Medical Coverage Policy | Microvolt T-Wave Alternans Testing



**EFFECTIVE DATE:** 01 | 20 | 2015  
**POLICY LAST UPDATED:** 04 | 20 | 2022

### OVERVIEW

Microvolt T-wave alternans (MTWA) testing has been investigated as a noninvasive test to identify a patient's risk for sudden cardiac death. The test measures the beat-to-beat microvolt variation in the amplitude of the electrocardiogram tracing. Some research indicates a positive test has a greater risk of developing ventricular tachyarrhythmias than a negative test.

### PRIOR AUTHORIZATION

#### Medicare Advantage Plans and Commercial Products

Prior authorization review is not required.

### POLICY STATEMENT

#### Medicare Advantage Plans

Microvolt T-wave alternans testing is covered.

**Note:** Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all Medicare Advantage Plans policies. Therefore, Medicare Advantage Plans policies may differ from Commercial products. In some instances, benefits for Medicare Advantage Plans may be greater than what is allowed by the CMS

#### Commercial Products

Microvolt T-wave alternans testing is not medically necessary as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### MEDICAL CRITERIA

Not applicable

### BACKGROUND

Microvolt T-wave alternans (MTWA) refers to a beat-to-beat variability in T-wave amplitude. Because a routine electrocardiogram (EKG) cannot detect these small fluctuations, this test requires specialized sensors to detect the fluctuations and computer algorithms to evaluate the results. T-wave alternans is measured by a provocative test that requires gradual elevation of the heart rate to more than 110 beats per minute. The test can be performed in conjunction with an exercise tolerance stress test. Test results are reported as the number of standard deviations (SDs) by which the peak signal of the T-wave exceeds the background noise. This number is referred to as the alternans ratio. An alternans ratio of 3 or greater is typically considered a positive result, an absent alternans ratio is considered a negative result, and other values are indeterminate.

The presence of T-wave alternans has been investigated as a risk factor for fatal arrhythmias and sudden cardiac death in patients with a history of myocardial infarction (MI), heart failure, or cardiomyopathy. Patients with these disorders at high-risk for sudden cardiac death may be treated with medications to suppress the emergence of arrhythmias or undergo implantation of cardiac defibrillators to terminate tachyarrhythmias when they occur. Since sudden cardiac death is one of the most common causes of death

after a MI or in patients with dilated cardiomyopathy, there is substantial interest in risk stratification to target therapy.

Patient groups are categorized into those who have not experienced a life-threatening arrhythmia (i.e., primary prevention) and those who have (i.e., secondary prevention). Those who have experienced a life-threatening arrhythmia are already at high risk and would not be considered for testing. T-wave alternans is one of many risk factors that have been investigated for identifying candidates for primary prevention. Others include left ventricular ejection fraction (LVEF), arrhythmias detected on Holter monitor or electrophysiologic studies, heart rate variability, and baroreceptor sensitivity. Signal-averaged electrocardiography (SAECG) is another technique for risk stratification. It measures beat-averaged conduction, while T-wave alternans measures beat-to-beat variability.

T-wave alternans has also been investigated as a diagnostic test for patients with syncope of unknown origin and as a noninvasive test to identify candidates for further invasive electrophysiology testing of the heart.

Microvolt T-wave alternans is one available method to risk stratify patients who may be at risk for sudden cardiac death and has been proposed to assist in selecting patients for implantable cardioverter-defibrillator (ICD) treatment. Results from prospective multicenter studies enrolling various patient populations undergoing ICD placement as part of primary prevention strategies do not support clinical utility from MTWA used to risk stratify and therefore guide placement. Therefore, this technology is considered not medically necessary.

T-wave alternans is considered not medically necessary as a technique of risk stratification for primary or secondary prevention\* of fatal arrhythmias and sudden cardiac death in patients with a history of myocardial infarction, congestive heart failure, cardiomyopathy or other cardiac disorders such as long-QT syndrome (e.g., Brugada syndrome).

\*Primary prevention refers to patients that have *not* experienced a life-threatening arrhythmia. Secondary prevention refers to patients that have experienced a life-threatening arrhythmia.

## **COVERAGE**

Benefits may vary between groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable machine tests or limitations of benefits/coverage when services are not medically necessary.

## **CODING**

The following code is covered for Medicare Advantage Plans and not medically necessary for Commercial products.

**93025** Microvolt T-wave alternans for assessment of ventricular arrhythmias

## **RELATED POLICIES**

Not applicable

## **PUBLISHED**

Provider Update June 2022

Provider Update, December 2021

Provider Update, June 2020

Provider Update, August 2019

Provider Update, January 2019

## **REFERENCES**

1. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002; 346(12):877-83.

2. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med* 1996; 335 (26):1933-40.
3. Buxton AE, Lee KL, Fisher JD et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med* 1999; 341(25):1882-90.
4. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Microvolt T-Wave Alternans Testing to Risk Stratify Patients Being Considered for ICD Therapy for Primary Prevention of Sudden Death. TEC Assessments 2005; Volume 20, Tab 9.
5. Chan PS, Gold MR, Nallamothu BK. Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. *J Cardiovasc Electrophysiol* 2010; 1(9):1009-14.
6. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Microvolt T-Wave Alternans Testing to Risk Stratify Patients Being Considered for ICD Therapy for Primary Prevention of Sudden Death. TEC Assessments 2006; Volume 21, Tab 14.
7. Bloomfield DM, Steinman RC, Namerow PB et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. *Circulation* 2004; 110(14):1885-9.
8. Hohnloser SH, Ikeda T, Bloomfield DM et al. T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. *Lancet* 2003; 362(9378):125-6.
9. Chow T, Kereiakes DJ, Bartone C et al. Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. *J Am Coll Cardiol* 2006; 47(9):1820-7.
10. Chan PS, Stein K, Chow T et al. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. *J Am Coll Cardiol* 2006; 48(1):112-21.
11. Calo L, De Santo T, Nuccio F et al. Predictive value of microvolt T-wave alternans for cardiac death or ventricular tachyarrhythmic events in ischemic and nonischemic cardiomyopathy patients: a meta-analysis. *Ann Noninvasive Electrocardiol* 2011; 16(4):388-402.
12. Merchant FM, Ikeda T, Pedretti RF et al. Clinical utility of microvolt T-wave alternans testing in identifying patients at high or low risk of sudden cardiac death. *Heart Rhythm* 2012; 9(8):1256-64 e2.
13. Gupta A, Hoang DD, Karliner L et al. Ability of microvolt T-wave alternans to modify risk assessment of ventricular tachyarrhythmic events: a meta-analysis. *Am Heart J* 2012; 163(3):354-64.
14. Salerno-Uriarte JA, De Ferrari GM, Klersy C et al. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. *J Am Coll Cardiol* 2007; 50(19):1896-904
15. Costantini O, Hohnloser SH, Kirk MM et al. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. *J Am Coll Cardiol* 2009; 53(6):471-9.
16. Ellenbogen KA, Levine JH, Berger RD et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? *Circulation* 2006; 113(6):776-82.
17. Chow T, Kereiakes DJ, Onufer J et al. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. *J Am Coll Cardiol* 2008; 52(20):1607-15.
18. Greenberg H, Case RB, Moss AJ et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). *J Am Coll Cardiol* 2004; 43(8):1459-65.
19. Chow T, Kereiakes DJ, Onufer J et al. Prognostic value of microvolt T-wave alternans in patients with moderate ischemic left ventricular dysfunction: results from the MASTER II trial (abstract). *J Am Coll Cardiol* 2008; 51(10):A17.

20. Gold MR, Ip JH, Costantini O et al. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. *Circulation* 2008; 118(20):2022-8.
21. Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation* 2006; 114(10):e385-484.
22. Verrier RL, Klingenhoben T, Malik M et al. Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility--consensus guideline by International Society for Holter and Noninvasive Electrocardiology. *J Am Coll Cardiol* 2011; 58(13):1309-24.
23. Decision Memo for Microvolt T-wave Alternans (CAG-00293N). 2008. Available online at: <http://www.cms.gov/medicare-coverage-database/details/ncddetails.aspx?NCDId=310&ncdver=2&CoverageSelection=National&Keyword=mtwa&KeywordLookUp=Title&KeywordSearchType=And&id=165&bc=gAAAABAAAA&>. Last accessed 4/2013.

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

